Genzyme Corp. (Sanofi Genzyme) has divulged emopamil-binding protein (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, transverse myelitis, neuromyelitis optica, optic ...
Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...
Genzyme, a subsidiary of Sanofi, has announced key data from its phase 3 clinical trials of its multiple sclerosis drug, Aubagio. The trials, called TOWER (Teriflunomide Oral in people With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback